Table 2

Effect of BMS-275291 at various dose levels in the Matrigel plug assay where mice were treated once daily for 7 days

Matrigel containing VEGF and bFGF was implanted subcutaneously into athymic mice on day 0. Daily BMS-275291 p.o. treatments began on day 0 and continued to day 6 (9–10 mice/group). Matrigel plugs were harvested on day 7 and processed for histochemical analyses. A result of ≥35% inhibition was considered active.
TreatmentMean no. of cells migrating into the Matrigel plugs ± SE% inhibition of cell migration ± SE (relative to control)
Untreated control6106 ± 163
BMS-275291
 90 mg/kg2577 ± 15058 ± 2.5
 60 mg/kg3272 ± 26846 ± 4.4
 30 mg/kg3640 ± 10440 ± 1.7
 10 mg/kg4280 ± 24429 ± 4.0
 1.1 mg/kg5113 ± 23516 ± 3.8
  • P < 0.05; P determined using the two-tailed Student t-test.